The market expects Warrior Met Coal (HCC) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be release ...

TORONTO, April 09, 2025 (GLOBE NEWSWIRE) -- Hanna Capital Corp. (the “Corporation”) is pleased to announce that it intends to raise gross proceeds of up to $500,000 through a non-brokered private placement of either (i) secured convertible debenture units (the “Debenture Units”) and/or (ii) units (the “Units”). Debenture Unit Offering Each Debenture Unit consists of $10,000 principal amount (the “Principal Amount”) of secured convertible debt (the “Debentures”) and 500,000 common share purchase warrants (th ...

Analyst's Disclosure: I/we have a beneficial long position in the shares of HCC either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Even as far back as the 19th century, receiving a lump of coal for Christmas was a sign of wrongdoing. Today, in the 21st century, with ESG and ...

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma (HCC)• Announced Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line HCC Pivotal Trial• Received FDA “Study May Proceed” letter for Phase 2 trial of TPST-1495 for the treatment of Familial Adenomatous Polyposis (FAP) BRISBANE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage bi ...

Bristol Myers (BMY) announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC), a type of liver cancer.This approval is based on results of phase III CheckMate -9DW clinical study demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investiga ...

Company Leadership Changes - Mike Schell will retire as President of Tokio Marine HCC on March 31, 2025, after over 50 years in the insurance industry [1][2] - Barry Cook, currently CEO of Tokio Marine HCC International, will take on the newly created role of Deputy CEO starting April 1, 2025 [1] Contributions and Achievements - Mike Schell has been a central figure at Tokio Marine HCC for 23 years, guiding the company through market cycles and contributing to its growth and success [3] - Under Schell's leadership, Tokio Marine HCC has achieved record performance, expanding its product offerings and global reach [3] Company Overview - Tokio Marine HCC is part of the Tokio Marine Group, which has a market capitalization of $70 billion as of December 31, 2024 [4] - The company is recognized as a leading specialty insurance group with strong financial ratings: 'A+' from S&P Global Ratings, 'A++' from AM Best, and 'AA-' from Fitch Ratings [4]

Warrior Met Coal (NYSE: HCC ) is a U.S. metallurgical ("met") coal mining company. The company has all its production in Alabama and due to the relative proximity of the mines to an export terminal in Mobile, WarriorIf you like this article and are interested in more frequent analysis of my holding companies, real-time notifications on portfolio changes, together with macro and industry analysis. I would encourage you to have a look at my marketplace service, Off The Beaten Path.I primarily invest in turnar ...

Financial Data and Key Metrics Changes - The company reported a net income of $1.1 million or $0.02 per diluted share for Q4 2024, a significant decrease from $129 million or $2.47 per diluted share in Q4 2023 [34] - Adjusted EBITDA for Q4 2024 was $53 million, down from $164 million in the same quarter last year, with an adjusted EBITDA margin of 18% compared to 45% in Q4 2023 [35][36] - Total revenues decreased to $297 million in Q4 2024 from $364 million in Q4 2023, primarily due to a 34% drop in average net selling prices [38] Business Line Data and Key Metrics Changes - Sales volume in Q4 2024 was 1.9 million short tons, up from 1.5 million short tons in the same quarter of 2023, driven by better production volumes [16][19] - Production volume increased to 2.1 million short tons in Q4 2024 from 2 million short tons in Q4 2023, with Mine 4 achieving a record high annual production of 2.8 million short tons [19][20] - The continuous miner units at the Blue Creek mine produced 170,000 short tons during Q4 2024, contributing to the overall production increase [21] Market Data and Key Metrics Changes - Sales by geography in Q4 2024 were 38% to Asia, 36% to Europe, and 25% to South America, with a notable shift from Europe to Asia compared to the previous year [17][18] - The primary index, PLD FOB Australia, ended Q4 at $178 per short ton, down $7 from the previous quarter, while the PLV CFR China Index ended at $180 per short ton [13] - Global pig iron production decreased by 1.8% in 2024, with China's production falling by 2.3% [14] Company Strategy and Development Direction - The company is focused on the Blue Creek growth project, which is expected to enhance production and profitability, with a total project investment of $717 million to date [25][29] - The company plans to ramp up production at Blue Creek to approximately 1 million short tons of high vol A steelmaking coal in 2025, with the longwall production expected to start no later than Q2 2026 [27][30] - The company maintains a disciplined capital spending approach and expects to complete the Blue Creek project within the estimated capital expenditure range of $995 million to $1.1 billion [29][28] Management's Comments on Operating Environment and Future Outlook - Management indicated that weak market conditions are expected to persist, with downward pressure on steelmaking coal prices due to excess Chinese steel exports and weak demand [11][49] - The company remains optimistic about its operational performance in 2025, anticipating higher sales and production volumes despite the challenging market environment [46] - Management emphasized the importance of maintaining strong customer relationships and a low-cost structure to navigate the current market dynamics [52][53] Other Important Information - The company generated cash from operations of over $370 million in 2024, with $43 million returned to stockholders via dividends [9] - Free cash flow for Q4 2024 was negative $88 million, primarily due to capital expenditures related to the Blue Creek project [44] - The company ended 2024 with total available liquidity of $655 million [45] Q&A Session Summary Question: Contribution from Blue Creek versus Mine 4 and Mine 7 - The company projects about 1 million tons from Blue Creek, with Mine 4 expected to produce over 2 million tons in 2025 [60][61] Question: Cash cost guidance reductions - The reduction in cash cost guidance is primarily attributed to lower net coal prices affecting transportation royalties [62][63] Question: Sales by geography and potential shifts - Tons that would have gone to China are still expected to flow into the Asian market, maintaining similar transportation costs [66] Question: Shipment timing for Blue Creek - The majority of Blue Creek's shipments are expected in the second half of 2025 [70] Question: Price realizations for High Vol A - Current realizations are expected to remain in the 85% to 90% range, with potential adjustments as volumes increase [72] Question: Inventory targets for year-end 2025 - The company aims to normalize inventory levels to a couple hundred thousand tons per mine by the end of 2025 [80] Question: New labor contract negotiations - Ongoing negotiations with the United Mine Workers are still in progress, with uncertain outcomes [93] Question: Future cash balance considerations - The company is evaluating the need for a higher minimum cash balance as Blue Creek operations ramp up [95]

February 13, 2025 Fourth Quarter and Full Year 2024 Results The revised project cost includes the original estimate of $700 million, plus scope changes of $120-$130 million, plus the impact of inflationary cost increases ranging from 25 to 35 percent. There have been no changes to the total project cost estimate range of $995 million to $1.075 billion. The estimated NPV, estimated IRR, estimated Payback calculation, projected valuation amounts, estimated production potential, anticipated schedule, estimated ...

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38061 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Warrior Met Coal, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizati ...